Eslicarbazepine acetate (Zebinix®), a voltage-gated sodium channel blocker, is a once-
daily, orally administered anti-seizure medication available in the EU for use as …

Eslicarbazepine acetate (Aptiom®) is a once-daily, orally administered antiepileptic drug
(AED) approved previously in the EU, USA and several other countries for use as adjunctive …

Abstract Eslicarbazepine acetate (Aptiom®, Zebinix®) is approved for the adjunctive
treatment of partial-onset seizures in adults aged≥ 18 years. Adjunctive therapy with oral …

Eslicarbazepine acetate is a is a once-daily antiepileptic drug (AED) that was approved in
2009 by the European Medicines Agency (EMA)(Zebinix™), and in 2013 by the US Food …

Eslicarbazepine acetate is an anticonvulsant medication approved in Europe for adjunctive
therapy in adults with partial-onset seizures. FDA approval is expected shortly for use in the …

Introduction: Eslicarbazepine acetate (ESL) is a third-generation antiepileptic drug (AED)
approved for adjunctive treatment in adults, children, and adolescents with focal-onset …

Eslicarbazepine acetate (ESL) is a once-daily antiepileptic drug that is approved as
adjunctive therapy in adults with focal-onset seizures. Following oral administration, ESL is …

Epilepsy is a common neurological disorder. Despite a broad range of commonly used
antiepileptic drugs, approximately 30% of patients with epilepsy have drug resistance or …

Purpose: To evaluate the long‐term efficacy and safety of once daily eslicarbazepine
acetate (ESL) as adjunctive therapy for partial‐onset seizures in adults with epilepsy …

Eslicarbazepine acetate (ESL), a new voltage-gated sodium channel blocker that is
chemically related to carbamazepine and partially metabolized to oxcarbazepine, has …